Study Finds Over 1 Million Americans Use GLP-1 Drugs Without Medical Reason

1-Minute Brief

The widespread use of GLP-1 drugs without clear medical justification raises questions about prescribing practices and drug accessibility.

Key Facts

• A study identified more than 1 million people in the U.S. taking weight-loss drugs without any apparent medical reason.
• Viking Therapeutics is developing VK2735, a GLP-1/GIP drug intended to compete with Eli Lilly’s Zepbound.
• VK2735 showed effectiveness in helping people maintain weight loss during a clinical trial, including those on a once-monthly regimen.
• The study on GLP-1 drug usage did not specify the reasons for off-label use among the identified individuals.
• Viking Therapeutics' stock price has increased following news about VK2735's clinical trial results.

What Happened

A recent study reported that over 1 million Americans are using GLP-1 weight-loss drugs without documented medical reasons. Meanwhile, Viking Therapeutics announced positive clinical trial results for its GLP-1/GIP drug VK2735.

Why It Matters

The findings highlight potential gaps in prescribing oversight and may influence regulatory scrutiny of weight-loss medications. New drug developments could further impact the market and patient access.

What's Next

Further investigation into prescribing practices and regulatory responses may follow the study's findings. Viking Therapeutics is expected to continue development and potential commercialization of VK2735.